Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Intrinsiqq's two-stage DCF values Eql Pharma AB (EQL.XSTO) at about SEK -2.21 per share, or SEK -1.66 with a 25% margin of safety. Every assumption is adjustable below; this is analysis, not investment advice.
Intrinsiqq's two-stage discounted cash flow (DCF) model estimates an intrinsic value of about SEK -2.21 per share for EQL.XSTO. It projects recent free cash flow forward at a growth rate that fades toward a long-run rate, then discounts those cash flows back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around SEK -1.66. The output moves with the growth and discount-rate inputs, so it is best read as a range, not a single number. You can change every assumption with the sliders on this tab.
The base case grows EQL.XSTO's free cash flow at about 8.0% a year before fading. If the price implies growth well above what the company has actually delivered, the market is paying for optimism; if below, expectations are modest. Adjust the growth assumption on this tab to see what the current price is really betting on.
A margin of safety is the discount to intrinsic value you demand before buying, to protect against being wrong on the inputs. Intrinsiqq applies 25% by default, which turns EQL.XSTO's SEK -2.21 intrinsic estimate into a SEK -1.66 entry. Wider margins suit less predictable businesses; you can set your own on this tab. This is analysis from SEC filings, not investment advice.